ReviewCurrent environmental health reports2024
Public Health Risks of PFAS-Related Immunotoxicity Are Real.
Review in Current environmental health reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Maternal perfluoroalkyl and polyfluoroalkyl substances (PFAS) exposure and preeclampsia: a systematic review and meta-analysis.BMC pregnancy and childbirth · 2025Pooled it
- Pooled it
- Derivation of guidance values under the EU Drinking Water Directive : the case study of trifluoroacetic acid.Archives of toxicology · 2026Review
- No clear evidence of PFAS-induced immunomodulation in SARS-CoV-2-specific human T cell responses following vaccination.Archives of toxicology · 2026Article
- PFAS: challenges and scientific perspectives in human health risk assessment.Archives of toxicology · 2026Article
- Exposure to per- and polyfluoroalkyl substances (PFAS) and development of autoimmunity in humans and animals: a scoping review.Archives of toxicology · 2026Article
- Probabilistic Concentration-Response Modeling and Risk Prioritization of Defined Mixtures of PFAS Using HumanEnvironmental science & technology · 2026Article
- The Role of ES&T in Advancing Environmental Toxicology and Chemical Risk Assessment: Past, Present, and Future.Environmental science & technology · 2026Review
- Developmental exposure to a PFAS mixture impairs the anamnestic response to influenza A virus infection in mice.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Per- and Polyfluoroalkyl Substances Exposure and Ischemic Heart Disease: Emerging Evidence from the Literature.Antioxidants (Basel, Switzerland) · 2026Review
- PFAS Toxicity: What's True, What's Not, and What Really Matters.Environmental science & technology · 2026Review
- Associations of serum PFAS with COVID-19 antibody levels among fully vaccinated adults.Environmental research · 2026Article
- Probiotic and Microbial Enzymatic Mechanisms for PFAS Detoxification.Probiotics and antimicrobial proteins · 2026Review
- Metabolomics of per- and polyfluoroalkyl substances (PFAS) exposure: Advances in LC-MS technology and applications.Journal of food and drug analysis · 2026Review
- Urine-to-Blood Partitioning of Per- and Polyfluoroalkyl Substances in Human Biomonitoring: Implications for Environmental Exposure Analysis and Bioaccumulation Assessment.Molecules (Basel, Switzerland) · 2026Review
- Will Chemical Exposomics Be Ready for a Human Exposome Project?Environmental science & technology · 2026Article
- Understudied PFAS precursors dominate household dust: insights from a pilot study in Rochester, NY.Journal of exposure science & environmental epidemiology · 2026Article
- Per- and polyfluoroalkyl substances (PFAS): persistence, toxicity, and emerging solutions.Bioprocess and biosystems engineering · 2026Review
- PFAS and One Health: integrating human, animal, and environmental perspectives.Archives of toxicology · 2026Review
- The Impact of Endocrine Disruptor Exposure During Pregnancy on Bacterial Complications and Viral Infections: A Narrative Review.Microorganisms · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purpose of reviewThe discovery of per- and polyfluoroalkyl substances (PFAS) in the environment and humans worldwide has ignited scientific research, government inquiry, and public concern over numerous adverse health effects associated with PFAS exposure. In this review, we discuss the use of PFAS immunotoxicity data in regulatory and clinical decision-making contexts and question whether recent efforts adequately account for PFAS immunotoxicity in public health decision-making. RECENT
findingsGovernment and academic reviews confirm the strongest human evidence for PFAS immunotoxicity is reduced antibody production in response to vaccinations, particularly for tetanus and diphtheria. However, recent events, such as the economic analysis supporting the proposed national primary drinking water regulations and clinical monitoring recommendations, indicate a failure to adequately incorporate these data into regulatory and clinical decisions. To be more protective of public health, we recommend using all relevant immunotoxicity data to inform current and future PFAS-related chemical risk assessment and regulation. Biological measures of immune system effects, such as reduced antibody levels in response to vaccination, should be used as valid and informative markers of health outcomes and risks associated with PFAS exposure. Routine toxicity testing should be expanded to include immunotoxicity evaluations in adult and developing organisms. In addition, clinical recommendations for PFAS-exposed individuals and communities should be revisited and strengthened to provide guidance on incorporating immune system monitoring and other actions that can be taken to protect against adverse health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.